Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Sponsor: Umoja Biopharma
Summary
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
Official title: A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
274
Start Date
2026-08
Completion Date
2031-08
Last Updated
2026-07-30
Healthy Volunteers
No
Conditions
Interventions
UB-VV400
UB-VV400 is a gene therapy that generates CD22-directed CAR T cells in the body.
Rapamycin (sirolimus)
Rapamycin is a drug approved by the FDA for indications unrelated to cancer.